Displaying drugs 626 - 650 of 11090 in total
Human botulinum neurotoxin A/B immune globulin
Infant botulism is a rare infectious disease occurring in infants in which Clostridium botulinum colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding...
Approved
Matched Description: … [L39819,L39824]
BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in …
Pegunigalsidase alfa
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … [L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with …
Equine Botulinum Neurotoxin E Immune FAB2
Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in...
Approved
Experimental
Investigational
Equine Botulinum Neurotoxin C Immune FAB2
Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in...
Approved
Experimental
Investigational
Indocyanine green
Approved
Experimental
Berotralstat
Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to...
Approved
Matched Description: … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral ... [L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health …
Zinc
A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound...
Approved
Investigational
Matched Description: … It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an ... polymorphism of the common polymorphism in zinc transporter _SLC30A8/ZnT8_ may increase susceptibility to type ... A newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated …
Matched Mixtures name: … Zinc Amino Acid Chelate Tab …
Matched Mixtures name: … Zinc Amino Acid Chelate Tab …
Pramipexole
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Description: … It was first approved by the FDA in 1997 [L5882]. ... This increase may be attributed to an aging population along with other contributing factors [A176861 ... In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA …
Desonide
A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
Approved
Investigational
Pentostatin
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Categories: … Nucleic Acid Synthesis Inhibitors …
Moroctocog alfa
Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. Moroctocog alfa is identical in sequence to endogenously produced Factor...
Approved
Matched Description: … Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and ... Moroctocog alfa is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid ... Unfortunately, purification of protein from human plasma carries an increased risk of transmission of …
Bacitracin
Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748]
Approved
Vet approved
Matched Iupac: … heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}-2-methylbutyl]carbamoyl}butanoic acid …
Rilmenidine
Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.
Approved
Investigational
Sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an …
Matched Categories: … Gastric Acid Lowering Agents …
Matched Categories: … Gastric Acid Lowering Agents …
Guanfacine
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an …
Calcium phosphate dihydrate
Approved
Treosulfan
Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.
Approved
Investigational
Padimate O
Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA . It is a structurally-related compound to DB02362 that absorbs UV-B rays to prevent photodamage. It penetrates human skin, and is shown to induce non-ligatable strand...
Approved
Matched Description: … Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in …
Pindolol
Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s....
Approved
Investigational
Trovafloxacin
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective...
Approved
Investigational
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid …
Denosumab
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263066]
Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Larotrectinib
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847] ... Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine ... kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important …
Oxolamine
Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation .
Approved
Matched Description: … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422]. ... Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant …
Bromocriptine
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Displaying drugs 626 - 650 of 11090 in total